Abstract
Deep venous thrombosis (DVT) is a relatively common, multifactorial disease, triggered by acquired or spontaneous factors. Since the molecular bases of DVT have not yet been fully unraveled, the activities and roles of biomolecules, metabolites of up to 1,200 Da, and blood cells are occupying become attractive subjects in medical scientific field. Our project aims to study metabolites involved in DVT and provide metabolomic and metabolic analysis by nuclear magnetic resonance techniques (NMR), which will be applied to liquid (serum) samples. It presents a pioneering and unprecedented approach, since there are no reports on the use of NMR in this area of research. The studies of patients with metabolomic DVT using mass spectrometry techniques (MS / MS UPLC) are also scarce. A recent study reports the identification of serum metabolites whose concentrations were altered when compared to patients with DVT and healthy controls. For example, lower concentrations of acylcarnitines (10: 1 and 16: 1), which could be associated with anticoagulant activity in the absence of phospholipids, were observed in patients. Metabolic changes in various lipids, especially steroids and amino acids, are being reported as promising to differentiate patients who presented an episode of thrombotic myocardial infarction from non-thrombotic myocardial infarction. However, due to the unpredictable nature of thrombosis, its complex etiology and the difficulty of animal models that mimic the human, studies of changes in the level of metabolites that may help in the early detection, diagnosis, progression or response to treatment of thrombosis. The purpose of this project is to use serum samples from patients with DVT to quantify metabolic and metabolic profile with the potential to predict the development, by means of quantitative analyzes of NMR metabolites, diagnosis or progression of the disease and to help understand the biology involved in it.
|